PTC Therapeutics (NASDAQ:PTCT)

CAPS Rating: 1 out of 5

Results 1 - 1 of 1

Recs

1
Member Avatar noataluren (< 20) Submitted: 5/28/2014 12:49:44 PM : Underperform Start Price: $23.38 PTCT Score: -70.28

As a former PTC employee, this recommendation for conditional approval is a joke. None of the data are strong. The improvement for the 40 mg/kg/day dose over placebo was significant (after eliminating 2 patients whose baseline data was faulty) in the DMD trial, however the results from the higher 80 mg/kg/day dose almost perfectly matched the placebo. Moreover, the CF Phase 3 trial was not only negative on the primary endpoint, but also on pretty much all the secondaries. Most importantly, the endpoint that was the primary in the Phase 2 studies in CF, used to show proof of concept, was highly nonsignificant in the Phase 3 study. Don't be surprised to see this one land flat on its face.

Results 1 - 1 of 1

Featured Broker Partners


Advertisement